Giovanni Roveroni
Research Subjects
Giovanni Roveroni has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Giorgio Gandini
Transfusion Medicine Department of Verona, University Hospital of Verona, Italy
2 shared publicationsAndrea Frigato
Transfusion Medicine Department of Rovigo, S. Maria della Misericordia Hospital of Rovigo, Italy
1 shared publicationAnnachiara Giuffrida
Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
1 shared publication- Arianna Veronesi
Transfusion Medicine Department of Treviso, Ca' Foncello Hospital of Treviso, Italy
1 shared publication Cristina Tassinari
Servizio Immunoematologia e Trasfusione, Centro Regionale per le Malattie del Sangue e Centro emofilia, ASL 8, Ospedale di Castelfranco Veneto, Castelfranco Veneto
1 shared publication- Ersilia Barbone
Transfusion Medicine Department of Belluno, San Martino Hospital of Belluno, Italy
1 shared publication
Latest Publications
- 1 August 2021
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 60 (4) , 103154
Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies
- 1 August 2021
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 60 (4) , 103154
Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies
- 1 January 2008
- Vol. 6 (1) , 8-11
Acquired haemophilia A as a blood transfusion emergency.
Acquired haemophilia is a rare autoimmune disorder caused by autoantibodies directed in the majority of the cases against clotting factor VIII. This disorder is characterised by the sudden onset of bleeding that not rarely may be life-threatening and need transfusion support. Most reports on this condition describe the need for blood transfusions during the acute, haemorrhagic phase, but the number of transfused red cell units is often unknown. In the last 5 years, 14 patients with acquired haemophilia A were identified in the transfusion and haemophilia centres of Verona and Castelfranco Veneto. The transfusion support for these 14 patients was analyzed in this retrospective survey. The 14 patients required a total of 183 red cell units. The average transfusion requirement was 13 red cells units/patient, with a range from 0 to 38 units. Eleven of the 14 patients studied needed strong transfusion support to enable any further management of the haemorrhages, as well as for eradication treatment of the autoantibodies to factor VIII. A relevant part of the management of haemorrhagic symptoms as well as the first choice for any further treatment (bleeding or the cure of the underlying disease) is transfusion of red blood cells.
- 1 January 2008
- Vol. 6 (1) , 8-11
Acquired haemophilia A as a blood transfusion emergency.
Acquired haemophilia is a rare autoimmune disorder caused by autoantibodies directed in the majority of the cases against clotting factor VIII. This disorder is characterised by the sudden onset of bleeding that not rarely may be life-threatening and need transfusion support. Most reports on this condition describe the need for blood transfusions during the acute, haemorrhagic phase, but the number of transfused red cell units is often unknown. In the last 5 years, 14 patients with acquired haemophilia A were identified in the transfusion and haemophilia centres of Verona and Castelfranco Veneto. The transfusion support for these 14 patients was analyzed in this retrospective survey. The 14 patients required a total of 183 red cell units. The average transfusion requirement was 13 red cells units/patient, with a range from 0 to 38 units. Eleven of the 14 patients studied needed strong transfusion support to enable any further management of the haemorrhages, as well as for eradication treatment of the autoantibodies to factor VIII. A relevant part of the management of haemorrhagic symptoms as well as the first choice for any further treatment (bleeding or the cure of the underlying disease) is transfusion of red blood cells.